Form 4: Clene Inc. Director Vallerie McLaughlin Granted Stock Options

Director Vallerie McLaughlin received stock options for 30,000 shares of Clene Inc. common stock on May 29, 2024.

Summary

• Vallerie McLaughlin, a director of Clene Inc., was granted stock options on May 29, 2024.
• The options are for 30,000 shares of Clene Inc. common stock.
• The exercise price is $0.37 per share.
• The options vest in 12 equal monthly installments starting June 29, 2024, and will be fully vested by May 2025.
• The options expire on May 28, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that the director is incentivized to contribute to the company's success.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of 12 months is typical, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies in the biotech space, such as BioNTech or Moderna, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates